Regina Hodits
Managing Partner @ Wellington Partners
Munich, Germany
Regina Hodits is a Series B investor at Wellington Partners in Munich focused on Health Care and Biotechnology. Regina Hodits is based out of Rome, Lazio and is the Managing Director of Angelini Ventures. Regina previously worked at EIT Health Germany as a Member of the Expert Council - Pro-Bono. Regina Hodits attended the TU Wien. Regina Hodits has received the Austrian Biochemical Society Prize.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 31%
Last updated:
For AI agents: llms.txt
Industries Regina Hodits invests in
Stages Regina Hodits invests in
Countries Regina Hodits invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 6 (38%)
- Biotechnology 5 (31%)
- Medical 4 (25%)
- Therapeutics 4 (25%)
- Medical Device 3 (19%)
Stage
- Series B 6 (38%)
- Series A 5 (31%)
- Series C 2 (13%)
- Seed 1 (6%)
Country
- France 2 (13%)
- United States 2 (13%)
- Denmark 1 (6%)
- Iceland 1 (6%)
- Switzerland 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| RougeTx is a Netherlands-based biotech developing first-in-class small-molecule therapies for vascular diseases caused by pericyte dysfunction. Its lead candidate, RTX-001, targets hereditary haemorrhagic telangiectasia (HHT), an inherited disorder involving fragile blood vessels and recurrent bleeding. | $58M / Series A / Oct 06, 2026 | ||
| NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics. | $33.6M / Series B / May 28, 2026 | ||
| SNIPR Biome is a operator of a discovery stage biotech company intended to revolutionize the treatment of microbial diseases. The company uses CRISPR technology that can subvert elements of the endogenous bacterial CRISPR machinery to eliminate hazardous bacteria in vivo, providing the health professionals with medicines that selectively target andkill bacteria with specific DNA sequences. | $40.9M / Series B / Aug 07, 2025 | ||
| NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics. | $131.8M / Series B / Jul 10, 2025 | ||
| Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $30M / Series C / Sep 21, 2022 | ||
| ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours. | $100M / Series C / Jun 13, 2022 | ||
| Sidekick is a patient-centric digital care platform that is scalable across a wide range of chronic illnesses. Sidekick makes healthcare more impactful, accessible, and efficient by developing and delivering digital health products that empower patients and digitize healthcare.The Sidekick platform combines an evidence-based clinical approachwith behavioral economics and gamification. Sidekick's platform approach transforms healthcare experiences, with one platform that integrates multi-chronic condition management and personalized care experiences.Sidekick partners with international pharmaceutical companies, payers and healthcare providers, helping them to put the people they serve first. | $55M / Series B / May 05, 2022 | ||
| Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $12M / Series B / Mar 01, 2021 | ||
| Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $47M / Series B / Jan 07, 2021 | ||
| Sidekick is a patient-centric digital care platform that is scalable across a wide range of chronic illnesses. Sidekick makes healthcare more impactful, accessible, and efficient by developing and delivering digital health products that empower patients and digitize healthcare.The Sidekick platform combines an evidence-based clinical approachwith behavioral economics and gamification. Sidekick's platform approach transforms healthcare experiences, with one platform that integrates multi-chronic condition management and personalized care experiences.Sidekick partners with international pharmaceutical companies, payers and healthcare providers, helping them to put the people they serve first. | $20M / Series A / Oct 28, 2020 | ||
| See all 16 investments → | |||
Co-Investors
About Wellington Partners
Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically lead financing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million. Wellington was established in 1998 and has offices in Munich, London, and Zurich.
Wellington Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Erich Schlick
General Partner
|
|||
Rolf Christof Dienst
General Partner and Founder Emeritus
|
|||
Anja Weibel
Finance Manager
|
|||
Frank Boehnke
General Partner
|
|||
Harald Keller
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Regina Hodits invest in?
Regina Hodits invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 16 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Regina Hodits?
Public channels for Regina Hodits include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Regina Hodits last invest?
The most recent investment recorded for Regina Hodits closed in Oct 2026. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
